Advance Metabolic Research with Mercodia’s Gut Hormone Assays
Gut hormones play a key role in metabolic disease research. Discover how Mercodia’s assays support precision and innovation in therapies for obesity, diabetes, and liver disease.
Mercodia: Cardiometabolic diseases, including diabetes, obesity, and cardiovascular conditions, are among the most pressing global health challenges.
At Mercodia, we specialize in cardiometabolic biomarker measurement, offering gold-standard immunoassays that enable researchers to generate high-quality data for drug development, clinical trials, and academic research.
Insulin is a cornerstone biomarker in metabolic research. Mercodia offers a range of insulin assays optimized for different sample types and study needs:
In the fight against obesity, GLP-1 and GIP are key biomarkers. These gastrointestinal peptides regulate satiety, glucose homeostasis, and energy balance, and are central to the development of next-generation weight-loss therapies.
Glucagon plays a vital role in glucose regulation, especially during fasting. Its secretion is influenced by diet, disease state, and organ interactions.
Oxidized LDL is a sensitive marker for atherosclerosis and cardiovascular disease. It is used to add predictive value beyond the traditional lipid profiles.
Lipoprotein(a), or Lp(a), is an independent and inherited risk factor for coronary and cerebrovascular disease. Elevated levels are associated with familial hypercholesterolemia and myocardial infarction.
Mercodia’s C-peptide assays support both low-level detection and standard-range quantification, giving researchers flexibility across a wide range of study designs.
At Mercodia, we go beyond providing high-quality immunoassays — we deliver a complete experience designed to support your research from start to finish.
We gladly support you by keeping you updated on our latest products and the developments around our services.